Alumis Inc.
ALMS
Rang în acțiuni
#10179
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Preț acțiune
$6.41
Ultima sincronizare: 2026-10-19
Capitalizare de piață
$830.25M
Schimbare (1 zi)
4.81%
Schimbare (1 an)
182.57%
Țară
US
Tranzacționează Alumis Inc. (ALMS)
Categorie
Healthcare
Raport P/S pentru Alumis Inc. (ALMS)
Raport P/S la data de October 2026 TTM: 0.00
Conform celor mai recente rapoarte financiare și prețului acțiunilor Alumis Inc., raportul P/S actual (TTM) este 0.00. La sfârșitul anului 2023, compania avea un P/S de 0.00.
Istoricul raportului P/S pentru Alumis Inc. din 2021 până în 2026
Raport P/S la sfârșitul fiecărui an
| An | Raport P/S | Schimbă |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2024 | 0.00 | 0.00% |
| 2023 | 0.00 | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
Raport P/S pentru companii similare sau competitoare
| Companie | Raport P/S | Diferență raport P/S | Țara |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
